Biohaven Ltd’s recently made public that its Director CHILDS JOHN W acquired Company’s shares for reported $1.0 million on Mar 04 ’25. In the deal valued at $30.47 per share,32,700 shares were bought. As a result of this transaction, CHILDS JOHN W now holds 2,320,571 shares worth roughly $69.29 million.
Then, CHILDS JOHN W bought 29,000 shares, generating $1,042,393 in total proceeds. Upon buying the shares at $35.94, the Director now owns 2,368,741 shares.
Before that, CHILDS JOHN W bought 21,052 shares. Biohaven Ltd shares valued at $999,970 were divested by the Director at a price of $47.50 per share. As a result of the transaction, CHILDS JOHN W now holds 21,052 shares, worth roughly $0.63 million.
Deutsche Bank initiated its Biohaven Ltd [BHVN] rating to a Buy in a research note published on February 11, 2025; the price target was $65. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Bernstein began covering BHVN with “an Outperform” recommendation on September 04, 2024. Morgan Stanley started covering the stock on July 24, 2024. It rated BHVN as “an Overweight”.
Price Performance Review of BHVN
On Friday, Biohaven Ltd [NYSE:BHVN] saw its stock fall -1.78% to $29.86. Over the last five days, the stock has lost -19.69%. Biohaven Ltd shares have fallen nearly -20.05% since the year began. Nevertheless, the stocks have fallen -49.09% over the past one year. While a 52-week high of $62.21 was reached on 02/11/25, a 52-week low of $26.80 was recorded on 03/04/25. SMA at 50 days reached $37.53, while 200 days put it at $40.56.
Levels Of Support And Resistance For BHVN Stock
The 24-hour chart illustrates a support level at 29.29, which if violated will result in even more drops to 28.72. On the upside, there is a resistance level at 30.75. A further resistance level may holdings at 31.65. The Relative Strength Index (RSI) on the 14-day chart is 28.07, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.79, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.08%. Stochastics %K at 16.35% indicates the stock is a buying.
The most recent change occurred on February 16, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $62 price target.
